

References

- **Abraham C and Medzhitov R.** Interactions between the host innate immune system and microbes in inflammatory bowel disease. *Gastroenterology*; 2011 ; 140(6), 1729-1737.
- **Aberra FN and Lichtenstein GR:** Review article: Monitoring of immunomodulators in inflammatory bowel disease. *Aliment Pharmacol Ther*; 2005; 21:307-319.
- **Abram, Clare L, Clifford A et al.;** (The Expanding Role for ITAM-based Signaling Pathways in immune cells). *Science Signaling* 2007 (377):re2.
- **Adler DG, Devila R, Oppenheimer GD et al:** American Society for Gastrointestinal Endoscopy. Appropriate use of gastrointestinal endoscopy. *Gastrointest Endosc*; 2000; 52:831-837.
- **Alberini JL, Ginzburg L, Crhon BB et al:** Technetium-99m HMPAO-labeled leukocyte imaging compared with endoscopy, ultrasonography, and contrast radiology in children with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr*; 2001; 32(3):278-86.
- **Arguelles-Arias F, Caunedo A, Romero J, et al.:** The value of capsule endoscopy in pediatric patients with a suspicion of Crohn's disease. *Endoscopy*; 2004; 36:869-873.
- **Arijs , Quintens R , Van Lommel et al.:** Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. *Inflammatory bowel disease*; 2010 ;.16 (12) 2090-2098.
- **Arnold GL, Beaves MR, Pryjdun VO, et al.:** Preliminary study of ciprofloxacin in active Crohn disease. *Inflamm Bowel Dis; Crohn's disease*; 2002; 8:10-15.
- **Assche GV, Vermeire S , Rutgeerts P et al.:** Focus on Mechanisms of Inflammation in Inflammatory Bowel Disease Sites of Inhibition: Current and Future Therapies. *Gastroenterology Clinics*; 2006 December; 35; 4.
- **Baldassarre ME, Altomare MA, Fanelli M, et al.:** Does calprotectin represent a regulatory factor in host defense or a drug target in inflammatory disease? *Endocr Metab Immune Disord Drug Targets*; 2007; 7:1-5.

- **Bamias,G.,Martin,C.,Marini,M.,et al.,** Expression , Localization and functional activity of TL1A,a novel Th1-polarizing cytokine in inflammatory bowel disease.J.Immunology.2003.171:4868-4874.
- **Bamias,G.,Martin,C.,Marini,M et al.,** Differential role of TH1 and TH2 cytokines in the pathogenesis of Samp1/YitFc ileitis.Gastroentrology 2004.126:A-119.
- **Bar-Meir S, Chowers Y, Lavy A, et al.:** Budesonide versus prednisone in the treatment of active Crohn disease. The Israeli Budesonide Study Group. Gastroenterology; 1998; 115(4):835-40.
- **Barmeyer C,Horak I,Zietz M,et al,** The interleukine-2-deficient mouse model. Pathology.2002.70:139-142.
- **Becker C,Fantini M,Schramm C, et al.** TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling .Immunology.2004,21:491-501.
- **Blank C and Keljo DJ.;** The History and Physical Exam in Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease; 2008; 14:224-227.
- **Blogowska A, Rzepka GI, Krzyzanowska SB et al.;** Is neuropeptide Y responsible for constitutional delay of puberty in girls? A preliminary report. Gynecol Endocrinol; 2004; 19(1):22-5.
- **Bojarski C,Weiske J ,Schoneberg T,et al.;** The specific fates of tight junction proteins in apoptotic epithelial cells.J Cell sci.2004,117:2097-2107.
- **Bonen,D.K.,Ogura,Y.,Nicolae,D.L. , et al.;** Crohn's disease associated NOD2 variants share a signaling defect in response to lipopolysaccharides and petidoglycan.Gastroenterology 2003.124:140-146.
- **Bongartz T, Sutton AJ, Sweeting MJ, et al.;** Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA; 2006; 295:2275-85.
- **Bruewer M,Utech M,I Vanov A, et al;** Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis like process.FASEB J.2005;19:923-933.

- **Both H, Pedersen TK, Kreiner S, et al.:** Clinical appearance at diagnosis of ulcerative colitis and Crohn's disease in a regional patient group. *Scand J Gastroenterol*; 2003; 18:987.
- **Bremner AR, M Giffiths, JD Argent, et al.:** Sonographic evaluation of inflammatory bowel disease: a prospective, blinded, comparative study. *Pediatr Radiol*; 2006; 36(9):947-953.
- **Camoglio, L Te velde A.A., de Boer A., et al.,** Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFFN-gamma receptor-deficient mice *Eur.J.Immunology* 2000.30:1486-1495.
- **Card T, Hubbard R , Logan RFA et al.:** Mortality in inflammatory bowel disease: a population-based cohort study. *Gastroenterology*; 2003; 125:1583-90.
- **Carvalho RS, Mahoney JA, Oliva-Hemker MM, et al.:** Inherent resistance to 6-thioguanine induced apoptosis correlates with disease activity in children with IBD. *Gastroenterology*; 2006; A203.
- **Caunedo A, Rodrigues-Tellex M, Garcia-Montes J, et al.:** Usefulness of capsule endoscopy in patients with suspected small bowel disease. *Rev Esp Enferm Dig*; 2004; 96:10-21.
- **Chamberlin W, Ghobrial G, Chehtane M et al.:** Successful treatment of a Crohn's disease patient infected with bacteremic *Mycobacterium paratuberculosis*. *Am J Gastroenterol*; 2007; 102:689-691.
- **Chinyu Su , Lichtenstein GR, Krok K et al:** Epidemiology of inflammatory bowel disease. *Feldman: Sleisenger & Fordtran's Gastrointestinal and Liver Disease*; 2006; 8; 109:2499-2500.
- **Chinyu Su ,Lichtenstein GR. R Mkhjian H et al:** Inflammatory bowel disease. *Feldman: Sleisenger & Fordtran's Gastrointestinal and Liver Disease*; 2006; 8; 108, 109:2459-2538.
- **Chong AKH, Taylor A, Miller A, et al.:** Capsule endoscopy vs. push enteroscopy and enteroclysis in suspected small-bowel Crohn's disease. *Gastrointest Endosc*; 2005; 61:255-261.
- **Ciarán P, Pierre KF ,Tom Oresland, et al.:** Inflammatory Bowel Disease. *Noble: Textbook of Primary Care Medicine*, 3rd ed.; 2001; 118.

- **Clark ML, MC Ald house Silk DBAet al.:** The pathology of inflammatory bowel disease. Gastrointestinal disease. Clinical Medicine, 6th edition; 2005; 6:265-346.
- **Clark M L and Silk DBA:** Epidemiology of inflammatory bowel disease. Gastrointestinal disease. Clinical medicine; 2005; 6; 6: 310.
- **Cleynen I, Mahachie John JM, Henckaerts L et al.:** Molecular reclassification of Crohn's disease by cluster analysis of genetic variants. Department of Gastroenterology (National center, for Biotechnology information Bethesda MD, USA. 2010. 5 (9), E12952.
- **Colombel JF, Sandborn WJ, Rutgeerts P, et al.:** Adalimumab for maintenance of clinical response and remission in patients with Crohn disease: the CHARM trial. Gastroenterology; 2007; 132:56-65.
- **Cominelli, F., Arseneau, K.O. and Pizarro, T.T.,** Cytokines and inflammatory mediators In Sartor, R.B. and Sandborn, W.J. (Eds.) Kirsner inflammatory Bowel Disease Elsevier Inc., London, GB 2004, pp 179-198.
- **Corbaz, A., ten Hove, T., Herren, S., et al.,** IL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's disease. J. Immunology 2002. 168:3608-3616.
- **Croese J, O'Neil J, Masson J, et al.:** A proof of concept study establishing *Necator americanus* in Crohn's patients and reservoir donors. Gut; 2006; 55:136-137.
- **Danese S, Semeraro S, Papa A, et al.:** Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol; 2005; 11:7227.
- **Darbari A, Kalloo AN, Cuffari C, et al.:** Diagnostic yield, safety and efficacy of push enteroscopy in pediatrics. Gastrointestinal Endoscopy; 2006; 64:224-8.
- **Dassopoulos T and Hanauer S:** Presentation and Diagnosis of Inflammatory Bowel Disease. Inflammatory Bowel Disease; 2007; 5:105-120.
- **Dejaco C, Harrer M, Waldhoer T, et al.:** Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn disease. Aliment Pharmacol Ther; 2003; 18:1113-1120.

- **Denning T, Kim G, Kronenberg M, et al.** Cutting edge: CD4⁺CD25⁺regulatory T cells impaired for intestinal homing can prevent colitis. *J Immunology* 2005;174:7487-7491.
- **Dieleman L, Goerres M, Arends A, et al.** Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. *Gut*. 2003;52:370-376.
- **Dubcenco E, Jeejeebhoy KN, Petroniene R, et al.:** Capsule endoscopy findings in patients with established and suspected small-bowel Crohn's disease: correlation with radiologic, endoscopic and histologic findings. *Gastrointest Endosc*; 2005; 62:538-544
- **Duerr RH, Taylor KD, Brant SR, et al.:** A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science*; 2006; 314:1461-3.
- **Dziki A and Galbfach P.:** Crohn's disease—when to operate? *Acta Chir Iugosl*; 2004; 51(2):61-8.
- **El Matary W, Zachos M, Spray C et al:** Nutritional Therapy. Medical management: Pediatric Inflammatory Bowel Disease; 2008; 26:337-350.
- **Eliakim R, Suissa A, Yassin K, et al.:** Wireless capsule video endoscopy compared to barium follow-through and computerized tomography in patients with suspected Crohn's disease—final report. *Dig Liver Dis*; 2004; 36:519-522.
- **Elliott DE, Urban JF, Argo CK, et al.:** Does the failure to acquire helminthic parasites predispose to Crohn's disease. *FASEB J*; 2000; 14:1848-1855.
- **Engelsgjerd M, Farraye FA, Odze RD et al.:** Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. *Gastroenterology*; 1999; 117:1288.
- **Escher JC, Taminiau JA, Nieuwenhuis EE, et al.:** Treatment of inflammatory bowel disease in childhood: best available evidence. *Inflammatory Bowel Diseases*; 2003; 9(1):34-58.

- **Fahlen L,Read S,Gorelik L,et al.** T cells that cannot respond to TGF-beta escape control by CD4⁺CD25⁺ regulatory Tcells.J Exp Med.2005;201:737-746.
- **Fantuzz,G.,Reed,D., Senaldi, G et al.,** Role of interferon regulatory factor-1 in the regulation of IL-18 production and activity.Eur.J.Immunol.2001. 31;369-374.
- **Feagan BG, Sandborn WJ, Baker JP, et al.:** A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn disease. Alimentary Pharmacology & Therapeutics; 2005; 21:373-384.
- **Feagan BG, Sandborn WJ, Lichtenstein G, et al.:** CDP517, a humanized monoclonal antibody to tumor necrosis factor-a, for steroid-dependent Crohn disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology & Therapeutics; 2006; 23:617-628.
- **Fioino G, Peyrine-Biroulet L, Balzrini Let al :** Adalimumab in ulcerative colitis:hypes and hopes.Exp.Opin Biol.Ther 2011 (1).109-116.
- **Fritz T,Niederreiter L,AdolphT, et al.** Crohn`s disease: NOD2,autophagy and ER stress converge. Gut doi:10.1136/gut.2009.206466.
- **Fuchizaki U, Machi T , Kaneko S et al.:** Clinical challenges and images in GI. Yersinia enterocolitica mesenteric adenitis and terminal ileitis. Gastroenterology; 2006; 131:1379, 1659.
- **Furukawa A, Saotome T, Yamasaki M, et al.:** Cross-sectional imaging in Crohn`s disease. Radiographics, 2004; 24(3):689–702. USA.
- **Gasche C, Lomer MC, Cavill I , et al.:** Iron, anaemia, and inflammatory bowel diseases. Gut; 2004; 53:1190-7.
- **Gilberts EC, Greenstein AJ, Katsel P, et al:** Molecular evidence for two forms of Crohn disease. Proc Natl Acad Sci U S A; 1994; 91:12721.
- **Girardin S,Boneca I,Cameiro L,et al** Nodi detects a unique muropeptide from gram-negative bacterialpeptidoglycan.Sience.2003;300:1584-1587..
- **Gotteland M, Brusner O , Cruchet S et al.:** Systematic review: are probiotics useful in controlling gastric colonization

by *Helicobacter pylori*. *Aliment Pharmacol Ther*; 2006; 23:1077-1086.

- **Gourtsoyiannis NC, Papanikolaou N , Karantanas A et al.:** Magnetic resonance imaging evaluation of small intestinal Crohn's disease. *Best Pract Res Clin Gastroenterol*; 2006; 20(1): 137-56.
- **Grilich C, Bogenrieder T, Palitzsch KD et al.:** Orofacial granulomatosis as initial manifestation of Crohn disease: a report of two cases. *European Journal of Gastroenterology & Hepatology*; 2002; 13:873-76.
- **Guslandi M, Giolla P , Testoni PA et al.:** Corticosteroid-sparing effect of Rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: preliminary clinical experience. *Current Therapeutic Research*; 2004; 65(3):292-96.
- **Hanauer SB, Sandborn WJ, Rutgeerts P, et al.:** Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. *Gastroenterology* 130; 2006; (2):323-333.
- **Hancock L, Windsor AC , Mortensen NJ et al.:** Inflammatory bowel disease: the view of the surgeon. *Colorectal Disease*; May 2006; 8(Suppl. 1):10-14.
- **Hara AK, Leighton JA, Sharma VK, et al.:** Small bowel: preliminary comparison of capsule endoscopy with barium study and CT. *Radiology*; 2004; 230:260-265.
- **Helmy,H and Grencis,R.K:** IL-18 regulates intestinal mastocytosis and TH2 cytokine production independantely of IFN-gamma during *Trichinella spiralis* infection. *J.Immunol.* 2002.169:2553-2560.
- **Haralambou G, Teirstein AS , Gil J et al.:** Present D. Bronchiolitis obliterans in a patient with ulcerative colitis receiving mesalamine. *Mt Sinai J Med*; 2001; 68:384-88.
- **Heyman MB, Kirschner BS, Gold BD, et al.:** Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. *Journal of Pediatrics*; 2005;146(1):35-40.

- **Horton KM, Corl FM, Fishman EK et al.:** CT evaluation of the colon: inflammatory disease. *Radiographics*;2000; 20(2):399-408.
- **Hoyer KK,Dooms H, Barron L, et al.:**Interleukine-2 in the development and control of inflammatory disease *Immunol.Rev*;2008; 226,19-28.
- **Hugot JP, Chamaillard M, Zouali H, et al.:** Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease; *Nature* ;2001;411. 599-603.
- **Hyams J, Crandall W, Kugathasan S et al.:** Induction and maintenance infliximab therapy for the treatment. *Gastroenterol*;2007; 132:863-73.
- **Isaacs KL, Lewis JD, Sandborn WJ, et al.:** State of the art: IBD therapy and clinical trials in IBD. *Inflammatory Bowel Diseases*;2005; 11 Suppl 1:S3-12.
- **Kanai,T,Watanabe, M.,Okamoto,S., et al .**Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn`s disease.*Gastroentrology*;2001; 121:875-888.
- **Karban A ,Itay M, Davidovich O, et al.:** Risk factors for perianal Crohn`s disease: the role of genotype, phenotype and ethnicity. *American Journal of Gastroenterology*;, 102:1702-1708(2007).
- **Khan WI, Blennerhasset PA., Varghese AK, et al.:** Intestinal nematode infection ameliorates experimental colitis in mice. *Infect Immun*;2007; 70:5931-5937.
- **Kieke,Michele C.Shusta, et al.** Selection of functional T cell receptor mutants from a yeast surface display library.Proceeding of the National Academy of Science of theUnited States of America 96(10):5651-5656.doi:10.1073/pnas.96.10,5651S.
- **Kiesslich R, Goetz M, Vieth M, et al.:** Confocal Laser Endomicroscopy. *Gastrointest Endosc Clin N Am*;2005; 15:715–31.
- **Kim S,Tonkonogy S,Albright C,et al.** Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria .*Gastoenterology*;2005;128:891-906.

- **Kishimoto T, Tagat T, Akira S, et al.** IL-6: from its discovery to clinical applications. *Immunol.*;2010; 22(5),347-352 .Japanese society of immunology .Japan.
- **Kornbluth, A, Hunt M, George J et al.:** An open label pilot trial of Rifaximin in the treatment of patients with refractory pouchitis. *Gastroenterology*;2006; 130: A-658 .
- **Kramer M, Netea M ,de Jong D, et al.** Impaired dendritic cell function in IBD patients with NOD2 3020insC mutation. *J Leuko .BIOL.*;2006;79:860-866 .
- **Krus T ,Brimnes J,Muong C, et al .** Induction of mucosal tolerance in peyers patche-deficient,ligated small bowel loops, *J Clin Invest.*;2005;115:2234-2243. .
- **Kugathasan S, Miranda A, Nocton J, et al.** Dermatologic manifestations of Crohn disease in children: response to infliximab. *J of Pediatr Gastroenterol Nutr*;2003; 37:150-154.
- **Kundhal P, Zachos M, Holmes JL et al.** Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. *J Pediatr Gastroenterol Nutr*;2001; 33(1):75-80.
- **Kundhal PS, Stormon MO, Zachos M, et al.:** Gastral antral biopsy in the differentiation of pediatric colitides. *Am J Gastroenterol*;2003; 98:557-561.
- **Kuzmic AC, Kolacek S, Brkljacic B et al.** Renal artery stenosis associated with Crohn`s disease. *Pediatric Nephrol*;2001; 16:371-73.
- **Lala S ,Ogura Y ,Osborne C,et al.** Crhons disease and the NOD2 gene :a role of paneth cells. *Gastroenterology*;2003;125:47-57.
- **Lakatos PL and Miheller P.** Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD? *Curr. Drug Targets* ;2011; (2):179-186 .
- **Leach MW,Davidson NJ,Fort MM,et al:** The role of IL-10 in inflammatory Bowel Disease. *Toxicol Pathol*;1999; 27:123-133.
- **Leighton JA, Shen BO, Baron TH, et al.:** Endoscopy in the diagnosis and treatment of inflammatory bowel disease. ASGE guideline. *Gastrointestinal Endoscopy*;2006; 63:558-65.

- **Liebermann, D.A and Holffman, B:** Myeloid differentiation .primary response genes in hematopoiesis. *Blood cells Mol.Dis*;2003;.31:213-228 .
- **Lesage S ,Zouali H,Cezard J, et al.** CARD15/NOD2 mutational analysis and genotype –phenotype correlation in 612 patients with inflammatory bowel disease .*Am J Hum GENET*;2002;70:845-857.
- **Leung, B.P., Culshaw, S., Gracie, J.A., et al** A role for IL-18 in neutrophil activation. *J.Immunol.*;2001; 176:2879-2886 .
- **Lemberg DA, Lessenman RM, Caudron R, et al.:** Positron emission tomography in the investigation of pediatric inflammatory bowel disease. *Inflammatory Bowel Disease*;2005; 11(8):733-8.
- **Loftus EV, Kane SV Bjorkman D et al:** Systematic review: Short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. *Aliment Pharmacol Ther*; 2004;19:179-89. .
- **Lossos A, River Y, Eliakim A, et al.:** Neurologic aspects of inflammatory bowel disease. *Neurology*;1999; 45:416.
- **Lugering A, Floer M, Westphal S, et al.** Absence of CCR6 inhibits CD4+ Regulatory T cells development and M cell formation inside Peyer's Patches. *Am J Pathol.*;2005;166:1647-1654.
- **Maccioni F, Colaiacomo MC, Parlanti S et al.:** Ulcerative colitis: value of MR imaging. *Abdominal Imaging*;2005; 30(5):584-92.
- **MacEneaney PM and Gasparaitis AE :** Radiological findings in inflammatory bowel disease. *Inflammatory Bowel Disease*;2007; 6:91-106.
- **Maconi G, Parente F, Bollani S, et al.:** Bowel ultrasound in Crohn's disease. *Best Pract Res Clin Gastroenterol*;2006;20(1):93-112.
- **Mader R, Segol O, Adawi M, et al.** Arthritis or vasculitis as presenting symptoms of Crohn's disease. *Rheumatol Int*;2005; 25:401-05.
- **Maeda S ,Hsu L, Liu H ,et al..** nod2 Mutation in Crhons disease potentiates NFF-Kappa B activity and IL-1 beta processing .*Science*;2005;307:734-738.

- **Mahadevan U , loftus Er, Sandborn WJ et al.:** Diagnosis and management of pouchitis. Gastroenterology;2003;124:1636(2003).
- **Mann E, AL-Hassi HO, Bernardo D, et al.** Homing of immune cells: role in homeostasis and intestinal inflammation. Inflamm. Bowel Dis.;2010;16:110,1966-1977 .
- **Margalit M, Elinav H, Shalit M et al.:** Liver abscess in inflammatory bowel disease: report of two cases and review of the literature. J of Gastroenterology and Hepatology;2004; 19:1338.
- **Markowitz J, Grancher K, Kohn N, et al.** A multi-center trial of 6-mercaptopurine and prednisone therapy in children with newly diagnosed Crohn disease. Gastroenterology; 2000;119(4):895-902.
- **Marmo R, Rotondano G, Piscopo R, et al.:** Capsule endoscopy versus enteroclysis in the detection of small-bowel involvement in Crohn's disease: a prospective trial. Clin Gastroenterol Hepatol; 2005; 3:772-776.
- **Mattei P and Rombeau JL.:** Surgical treatment of ulcerative colitis. Surgical Management. Pediatric Inflammatory Bowel Disease; 2008;36:469-483.
- **May A, Nachbar L, Wardek A, et al.:** Double balloon enteroscopy: preliminary experience with obscure gastrointestinal bleeding or chronic abdominal pain. Endoscopy;2003; 35:985-91.
- **McQuaid KR, Laine L , Souza R, et al.:** Inflammatory bowel disease. Current medical diagnosis and treatment; 2005; 44; 14: 602-612.
- **Mesquita MB, Civitelli F, Levine A, et al.:** Epidemiology, genes and inflammatory bowel disease in childhood, Digestive and Liver Disease, Science Direct; 2007;November; 40:3-11.
- **Montgomery SM, Morris DL, Pounder RE , et al.:** Asian ethnic origin the risk of inflammatory bowel disease. European Journal of Gastroenterology and Hepatology; 1999; 11:543-546.
- **Moreels TG, Nieuwendijk RJ, De Man JG, et al.:** Concurrent infection with *Schistosoma mansoni* attenuates inflammation-induced changes in colonic morphology, cytokine

levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats. Gut;2004; 53:99-107.

- **Moustafa .M,** Szabo M, Ghanem G, et al .Inhibition of tumor necrosis factor-alpha stimulated NFkappaB/p65 in human keratinocytes by alpha –melanocyte stimulating hormone and adrenocorticotrophic hormone peptides.J Invest Dermatol.;2002;119 :1244-1253.
- **Mow WS, Lo SK, Targan SR, et al.:** Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. Clin Gastroenterol Hepatol;2004;2:31-40.
- **Muzio,M.,Polentarutti, N., Bosisio,D.,N et al.:** Toll-like receptors: agrowing family of immune receptors that are differentietely expressed and regulated by different leucocytes .J.Leukoc.Biol.;2000; 67: 450-456.
- **Nakanishi,K.,Yoshimoto,T.,Tsutsui,H. et al :**interleukine-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu.Cytokine Growth Factor Rev.;2001; 12:53-72.
- **Nash S and Heuertz RM:**Blockade of p38 map Kinase inhibits complement-induced acute lung injury in amurine model.INT.Immunopharmacol.;2005; 5:1870-1880.
- **Netea M,Ferwerda G,de Jong D,et al.**The frameshift mutation in Nod2- but also Nod1-activating peptidoglycan agonists. J Biol Chem ;2005;280:35859-35867.
- **Nancy MG and Judy HC:** Genetics of Inflammatory Bowel Diseases, Pediatric Inflammatory Bowel Disease;2006; 3:33-43
- **Neurath MF, Markus F, Fuss U, et al.:** IL-23: a master regulator in Crohn disease. Nature Medicine; 2007;13:26-8.
- **Noble A, Baldassano R Mamula P et al.:** Novel therapeutic options in the inflammatory bowel disease world, digestive and liver disease, article, Science Direct; 2007.
- **Nwomeh BC and Crandall WV:** Radiological evaluation of inflammatory bowel disease. Pediatric Inflammatory Bowel Disease; 2008; 17:192-209.
- **Ogura,Y.,Bonen,D.K.,Inohara,N.,et al.:** Aframeshift mutation inNOD2 associated with susceptibility to crhons disease.Nature.;2001;411:603-606.

- **Ohkusa T, Nomura T, Terai T, et al.:** Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. *Scand J Gastroenterol*; 2005;40:1334-1342.
- **Oliva-Hemker M, Brakenhoffl K, Vander Heijde DM, et al.:** More than a gut reaction: Extraintestinal complications of IBD. *Contemporary Pediatrics*; 16:45. (1999).
- **Panaccione R, Baumgart ,Dignass , et al.:** Methotrexate: lessons from rheumatology. *Can J Gastroenterol*;2005; 9:541-42.
- **Panaccione R , Gamelli A, Sandborn W et al;** Briakinumab (ABT874) for treatment of Crohn's disease. *UEGW*, 2011;674-688. , Vienna, Australia
- **Papadakis KA, Yang H, Ippoliti A, et al.:** Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. *Inflamm Bowel Dis*; 2007; 13:524-30.
- **Parente F, Cucino C, Bollani S, et al:** Focal gastric inflammatory infiltrates in inflammatory bowel diseases: Prevalence, immunohistochemical characteristics and diagnostic role. *Am J Gastroenterol*;2000; 95:705.
- **Peltekova V, Wintle R, Rubin L, et al.** Functional variants of OCTN cation transporter genes are associated with Crohn's disease .*Nat Genet.*;2004;36:471-475.
- **Peluso I, Pallone F, Monteleone G et al.:** Interleukin-12 and Th1 immune response in Crohn disease: patho-genetic relevance and therapeutic implication. *World Journal of Gastroenterology*;2006; 12:5606-10.
- **Peppercorn MA and Moss AC:** Inflammatory Bowel Disease. IN: Rakel: Conn's Current Therapy 2007, 59th ed.
- **Perencevich M and Burakoff R.:** Use of antibiotics in the treatment of inflammatory bowel disease. *Inflamm. Bowel Dis*;2006; 12:651-664.
- **Pimentel M, Chang M, Chow EJ, et al.:** Identification of a prodromal period in Crohn's disease but not ulcerative colitis. *Am J Gastroenterol*;2000; 95:3458.
- **Plevy SE, Salzbert B, vanAssche G, et al:** A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe

steroid-refractory ulcerative colitis: results of a Phase I study. *Gastroenterology*;2004;126. (4): A75.

- **Poggioli G, Pierangeli F, Laureti S, et al.:** Review article: indication and type of surgery in Crohn's disease. *Aliment Pharmacol Ther*; Jul;2002; 16 Suppl 4:59-64.
- **Polman CH, O'Connor PW, Havrdova E, et al.:** A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *New England Journal of Medicine*; 2006;354:899-910.
- **Putoczki T and Ernst M :** More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. *J.Leukoc.Biol.*;2010; 88 (6),1109-1117 .
- **Rabizadeh S and Oliva-Hemker M:** Extraintestinal Manifestations of pediatric inflammatory bowel disease. *Pediatric Inflammatory Bowel Disease*;2008; 9:139-152.
- **Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al.** Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. *Cell*.;118:229-241. (2004).
- **Rejchrt S, Bures J, Siroky M, et al.:** A prospective, observational study of colonic mucosal abnormalities associated with orally administered sodium phosphate for colon cleansing before colonoscopy. *Gastroint Endosc*;2004; 59:651-654.
- **Reinisch W and Bene L:** Fontolizumab in moderate to severe Crohn's disease .a phase 2, randomized double-blind placebo-controlled multiple-dose study .*Inflammatory Bowel Disease*;2010;16(2),233-242 .
- **Ricart E and Sandborn WJ:** Extraintestinal manifestations of inflammatory bowel disease. *Inflammatory Bowel Disease*; 2007;19:257-278 .
- **Riddell RH, Kirsner JB, Shorter RG et al.:** Pathology of idiopathic inflammatory bowel disease. In: Kirsner JB, ed. *Inflammatory Bowel Disease*:2000; 427 -452. (2000).
- **Rioux KP and Fedorak RN.:** Probiotics in the treatment of inflammatory bowel disease. *J Clin Gastroenterol*;2006; 40:260-263 .

- **Rivera-Nieves J, Olson T, Bamias G, et al.:** L-selectin, alpha 4 beta 1, alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine J Immunol;2005;174 :2343-2352 .
- **Robbins and Cotran:** Kumar: Pathologic Basis of Disease, 7th ed.; 2005.
- **Rosh JR, Otley AR, Bousvaros A, et al.:** Methotrexate Therapy. Medical Therapy of inflammatory bowel disease. Pediatric inflammatory bowel disease;2008; 30(4):307-451.
- **Rothfuss KS, Stange EF ,Herrlinger KR et al.:** Extraintestinal manifestations and complications in inflammatory bowel disease. World J Gastroenterol;2006; 12:4819 .
- **Rowe WA:** Inflammatory bowel disease, article, e Medicine; 2007.
- **Rudick RA, Stuart WH, Calabresi PA, et al.:** Natalizumab plus interferon beta-1a for relapsing multiple sclerosis .New England Journal of Medicine;2006; 354:911-23 .
- **Russo P, Cohen AB, Mamula P et al.:** The pathology of chronic inflammatory bowel disease in: Pediatric Inflammatory Bowel Disease;2008; 19:342-380 .
- **Rutgeerts P, Sandborn WJ, Feagan BG, et al.:** Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med;2005; 353:2462-2476 .
- **Rutgeerts P, Hiele M, Geboes K, et al.:** Strategies in the prevention of post-operative recurrence in Crohn's disease. Best Pract Res Clin Gastroenterol;2003; 17: 63-73 .
- **Rutter M, Saunders B, Wilkinson K, et al:** Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology; 2004; 126:451.
- **Saeed S and Kugathasan S:** Epidemiology of Pediatric Inflammatory Bowel Disease, Pediatric Inflammatory Bowel Disease;2008; 4; 83:102 .
- **Sandborn W, Colombel J, Enns R, et al.:** Maintenance therapy with natalizumab does not require use of concomitant immunosuppressants for sustained efficacy in patients with active Crohn's disease: results from the ENACT-2 study. Gastroenterology;2006; 130:A-482 Abstract 1137 .

- **Sandborn W, Gasink C, Gao LL et al.** A multicenter, randomized double-blind placebo-controlled phase 2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40 in patients with moderately to severely active Crohn's disease: results through week 22 from the certifi trial. Presented at :Digestive Disease Week.Chicago,IL,USA, May 2011;7-10 .
- **Sandborn WJ, Loftus E, Silverstein MD, et al.:** Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance and chemoprevention. Rev Gastroenterol Disord;2006; 6:97-105.
- **Sandler, R.S. Loftus, E.V.Jr. et al.** Epidemiology of inflammatory bowel disease In: Sartor, R.B. and Sandborn, W.J. (Eds.) Kirsnes inflammatory bowel disease. Elsevier Inc., London. BG, pp 2006; 254-262.
- **Sands BE, Kozarek R, Spainhour J, et al.:** Safety and tolerability of concurrent natalizumab treatment for patients with Crohn disease not in remission while receiving infliximab. Inflammatory Bowel Disease; 2007;13:2-11.
- **Sands BE, Lichtenstein GR, Pazianas H, et al.:** From symptom to diagnosis: Clinical distinctions among various forms of intestinal inflammation. Gastroenterology; 2004; 126:1518-32.
- **Sands BE, Winston BD, Salzberg B, et al.:** Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther;2002 16:399-406.
- **Saraiva M, O Garra, A, Evdemon, et al.:** The regulation of IL-10 production by immuncells. Nat.Rev.Immunol;2010;.10(3),170-181 .
- **Schraut WH, O'Garra, Evdemon-Hong M, et al.:** The surgical management of Crohn's disease. Gastroenterol Clin North Am; 2002;31(1):255-63
- **Schwartz DA and Herdman CR.:** Review article: the medical treatment of Crohn perianal fistulas. Aliment Pharmacol Ther;2004; 19:953-967.

- **Shafraan I, Johnson LK, Hammle, et al.:** An open-label evaluation of rifaximin in the treatment of active Crohn disease. *Cur Med Res Opin*;2005; 21:1165-69.
- **Shapiro W:** Inflammatory bowel disease, article, *e Medicine*; 2006.
- **Shen C, Assche GV, Colpaert S, et al.:** Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. *Alimentary Pharmacology & Therapeutics*;2005; 21:251-8.
- **Shen C, Van Assche G, Rutgeerts P, et al.:** Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. *Inflammatory Bowel Diseases*;2006; 12:22-8.
- **Siegmund, b., Sennello, J.A., Lehr, H.A et al.:** Interferon regulatory factor-1 as a protective gene in intestinal inflammation: role of TCR gamma delta T cells and interleukine-18-binding protein. *Eur. J. Immunol.* 2004. 34: in press..
- **Silverberg MS, Satsangi J, Ahmad T, et al.:** Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol*;2005;19. (Suppl A):5-36.
- **Simms L and, Steinhart AH:** Budesonide for maintenance of remission in Crohn disease. *Cochrane Database Syst Rev*;2001; 2001(1):CD002913 .
- **Sinha A, Nightingale J, West KP, et al.:** Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. *N Engl J Med*;2003;349:350-357.
- **Smith AM, Rahman FZ, Hayee B et al .:** Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. *J. Exp. Med.* 2009;206(9),1883-1897 .
- **Solem CA, Harmsen WS, Zinsmeister AR, et al.:** Small intestinal adenocarcinoma in Crohn's disease: a case-control study. *Inflammatory Bowel Disease*;2004; 10:32-35.

- **Solem CA, Loftus EV, Fletcher JG, et al.:** Small bowel (SB) imaging in Crohn's disease (CD): a prospective, blinded, 4-way comparison trial. *Gastroenterology*; 2005;128:A74.
- **Sugawara S., Uehara, A., Nochi, T., et al.:** Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. *J. Immunol.* 2001; 167:6568-6575.
- **Soderholm J, Streuter C, Yang P, et al.** Increased epithelial uptake of protein antigen in the ileum of Crohn's disease mediated by tumor necrosis factor alpha. *Gut*. 2004; 53:1817-1824 .
- **Steidler L, Neirynck S, Huysghebaert N, et al.** Biological containment of genetically modified *Lactococcus Lactis* for intestinal delivery of human interleukin 10. *Nat Biotechnol.* 2003; 21:785-789.
- **Summers RW, Elliott D E, Weinstock J V, et al.:** Novel and Future Medical Management of Inflammatory Bowel Disease. *Surgical Clinics of North America*; June 2007; Volume 87, Issue 3. 727-741.
- **Tamboli CP, Hugot JP, Colombel J F, et al.:** Current Medical Therapy for Chronic Inflammatory Bowel Diseases. *Surgical Clinics of North America*; June 2007;. Volume 87, Issue 3; 697-725.
- **Tanaka M, Riddell RH, Saito H, et al.:** Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis. *Scand J Gastroenterol*; 1999; 34:55-67
- **Tanaka M, Saito H, Kusumi T, et al.:** Spatial distribution and histogenesis of colorectal Paneth cell metaplasia in idiopathic inflammatory bowel disease. *Journal of Gastroenterology and Hepatology*; 2001; 16:1353-1359 .
- **Tobin JM, Sinha B, Ramani P, et al.:** Upper gastroin-testinal mucosal disease in pediatric Crohn's disease and ulcerative colitis: a blinded, controlled study. *J Ped Gastroenterol Nutri*; 2001; 32: 443-448 .
- **Togashi K and Konishi F:** Magnification Chromo-colonoscopy. *ANZ J Surg*; 2006; 76:1101-5 .

- **Travis SP, Stange EF, Lemann M, et al.:** European evidence based consensus on the diagnosis and management of Crohn disease: current management. *Gut*; 55(Suppl 1)2006;:16-35.
- **Turner D, Grossman AB, Rosh J, et al.:** Methotrexate following unsuccessful thiopurine therapy in pediatric crohn's disease. *Am J Gastroenterol*; 2007;102:1-9.
- **Tsuchiya,T.,Fukuda,S.,Hamada,H., et al.:** Role of gamma delta T cells in the inflammatory response of experimental colitis mice.*J.Immunol.*2003; 171: 5507-5513.
- **Uhlen S, Belbouab R, Narebski K, et al.:** Efficacy of Methotrexate in Pediatric Crohn's Disease: A French Multicenter Study. *Inflamm Bowel Dis*; 2006;12:1053-57 .
- **Ullman T, Croog V, Harpaz N, et al.:** Progression of flat low-grade dysplasia to advanced neoplasia in patients withulcerative colitis. *Gastroenterology*;2003; 125:1311.
- **Valdez R, Appelman HD, Bronner MP, et al.:** Diffuse duodenitis associated with ulcerative colitis. *Am J Surg Pathol*;2000; 24: 1407-1413.
- **Van Assche G, Paintaud G, D'Haens G, ,et al.:** Continuation of immunomodulators is not required to maintain adequate infliximab efficacy in patients with Crohn disease but may improve pharmacokinetics. *Gastroenterol Suppl*;2006; 130: A-142 .
- **Vande Casteele N,Ballet V, Van Assche G, et al.** Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatmrnt *Gut* doi2011;:10.1136/gut 2010.236869 .
- **Venkatesh and Thomson:** Endoscopic modalities of in inflammatory bowel disease. *Pediatric Inflammatory Bowel Disease*; 2008;18:210-240 .
- **Vermeire S, Assche GV, Rutgeerts P, et al.:** Infliximab Therapy. *Medical Therapy of inflammatory bowel disease. Pediatric inflammatory bowel disease*;2008 ;31:387-401.
- **Vermeire S and Rutgeens P,:** **A Phase 2a A** multicenter,randomized double-blind placebo-controlled **dose** escalation study to evaluate the safety tolerability, pharmacodynamics and efficacy of AGO11 in patients with

moderately active ulcerative colitis. Presented at :Digestive Disease Week.New Orleans,LA,USA2010;1-5 .

- **Voderholzer WA, Beinhoelzl J, Rogalla P, et al.:** Small bowel involvement in Crohn's disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. *Gut*;2005; 54:369-373.
- **Vos AC, Wildenberg ME ,Duijvestein M,et al .:**Anti-tumor necrosis factor – a antibodies induce regulatory macrophages in an Fc region-dependent manner.*Gastroenterology* ;2011;140(1),221-230.
- **Walker TR and Kartashov A,:** Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr*; 2007; 44:414-22.
- **Wehkamp J,Harder J,Weichthal M, et al.:** *NOD2* mutations in inflammatory bowel disease associated with diminished mucosal alpha-defensin expression.*Gut* 2004;53: 1658-1664.
- **Weinstock JV, Summers RW ,Elliott DE, et al.:** Helminths and harmony: mounting evidence suggests that helminths help regulate mucosal inflammation. *Gut*;2006 53:7-9.
- **Weinstock JV, Summers RW , Elliott DE et al.:** Role of helminths in regulating mucosal inflammation. *Springer Semin Immunopathol*;2005; 27:249-271.
- **Wilson A, Reyes E , Ofman J et al:** Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. *Am J Med*; 116 Suppl 7A:2004;44S-49S.
- **Winawer S, Fletcher R, Rex D, et al:** Colorectal cancer screening and surveillance: Clinical guidelines and rationale-update based on new evidence. *Gastroenterology*;2003; 124:544.
- **Wirz S and Neurath MF:**Animal models of intestinal inflammation:new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease.*INT J colorectal Disease* 2000;15: 144-160.
- **K,Liu Y and Mccall IC:** Neutrophil migration across tight junction is mediated by adhesive interactions between epithelial coxsackie and adenovirus receptor and a junctional adhesion molecule-like protein on neutrophils.*Mol Biol Cell*. 2005;16:2694-2703

- **Zholudev A, Zurakowski D, Young W, et al.:** Serologic testing with ANCA, ASCA and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. *Am J Gastroenterol*; 2004; 99:2235-41.
- **Zwerina J, Hayer S, Redlich K, et al.** Activation of p38 MAPK is a key step in tumor necrosis factor –mediated inflammatory bone destruction. *Arthritis Rheum*. 2006;54: 463-472.